You just read:

ThromboGenics Enrolls First Patient in Phase II CIRCLE Trial Evaluating Multiple Doses of Ocriplasmin to Induce a Total Posterior Vitreous Detachment in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)

News provided by

ThromboGenics

13 Jan, 2016, 06:30 GMT